C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis

摘要

Methods for reducing bleeding during fibrinolysis treatment and for inhibiting the enzymatic activity of a two-chain urokinase mutant are described. Exogenous C1-inactivator is administered during fibrinolysis treatment with the pro-urokinase mutant polypeptide, M5. The C1-inactivator inhibits the formation of two-chain M5 resulting in less hemostatic bleeding.